ResoTher Pharma is a biotechnology company focused on developing a novel class of peptide therapeutics
Our drugs target neutrophil driven inflammation and act as resolution therapy
To unlock the promise of resolution therapy
To create novel medicines that benefit patients in need
About ResoTher Pharma
ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin A1 as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role. Our current focus is on cardiovascular disorders and inflammatory disorders with a large unmet medical need.
The company’s assets and discoveries are based on work performed by Professor Mauro Perretti and his team at the Queen Mary University in London, UK. Professor Perretti is a pioneer in the area resolution therapy and has spent decades pinpointing the role of Annexin A1 and its receptors in the resolution of chronic inflammation.
ResoTher Pharma is a biotechnology company focused on developing a novel class of therapeutics that rapidly cause resolution of inflammation. Our peptide drugs mimic the body’s natural response to resolving inflammation and initiating tissue repair through their actions on the FPR2 receptor, a G-protein coupled receptor expressed on the surface of leukocytes. Our drug candidates are potent immune modulators and have shown excellent safety and efficacy in a variety of inflammation-driven disease models.
Chronic inflammation is a primary driver in a variety of disease states and adversely affect human health in a myriad of ways. At ResoTher Pharma, we focus on the role of endogenous immune effectors in the propagation and resolution of chronic inflammation. We seek to clinically validate a variety of Annexin A1-derived peptides as a novel therapeutic class in indications where neutrophils are the main perpetrators of exacerbated inflammation.
We take an active partnering approach and welcome inquiries for collaboration around our assets.
The ResoTher Pharma Team
Lone Veng, PhD
Chief Executive Officer
Lone Veng is a pharmaceutical executive with a career background in pharmaceutical R&D. Dr Veng has operational leadership experience from both small and large organizations and has always worked at the intersection of business and innovation. Most recently, Dr. Veng served as CEO and co-founder of Clinical Microbiomics. During her career, she has held various senior research leadership roles, such as Head of Pharmacology and Head of DMPK at companies such as LEO Pharma, Merck & Co, and H. Lundbeck. Dr. Veng has overseen the drug discovery, nomination and clinical transition of a number of drug candidates for inflammatory and neurological disorders.
Thomas Jonassen, MD
Chief Science Officer
Thomas Jonassen is an experienced biotech entrepreneur, having founded a number of successful biotech companies. He is the former co-founder and Chief Science Officer of Action Pharma (sold to Abbvie in 2012). TXP-Pharma (main asset sold to Questcor Pharmaceuticals in 2015) and presently also serves as CSO at SynAct Pharma, a biotech company focused on novel therapeutics for inflammatory joint disorders. In addition to these roles, Dr. Jonassen is associate professor at the University of Copenhagen in the department of Cardiovascular Pharmacology and an honorary professor at William Harvey Research Institute at the Queen Mary University in London.
Chief Development Officer
Paul Hargreaves is an executive with over 25 years’ experience in pharmaceutical R&D. He has extensive clinical leadership experience and is recognised for his business acumen and innovative thinking that have enabled the successful global registration of many products. Most recently, Mr. Hargreaves was the Global Head of Clinical Operations at LEO Pharma. He previously held senior leadership roles at both Pfizer and Quintiles. Mr. Hargreaves has hands-on experience across the development continuum – including market access and business development activities – and within many therapeutic areas including cardiology, oncology, CNS, urology and dermatology.
Board of Directors
Kirsten Drejer, PhD
Kirsten Drejer has a long standing experience as a successful biotech entrepreneur, having co-founded Symphogen A/S and served as CEO for 16 years. During that time, Symphogen grew from a start-up to one of the most innovative and successful clinical-stage biotechs in Europe. Dr. Drejer now serves on the boards of Zealand Pharma, BioPorto, Bioneer, Antaq Therapeutics among others.
Jeppe Øvli Øvlesen, MBA
Jeppe Øvlesen is an experienced biotech entrepreneur and has been involved as founder/CEO/Chairman in a string of successful companies including Action Pharma, CLC Bio, Cetrea, ChemoMetec, Monsenso, PNN Medical, and TXP Pharma. Mr. Øvlesen is co-founder and presently serves as CEO of SynAct Pharma, which is listed on the Swedish small-cap exchange Aktietorget.
Henrik Stage, MS
Henrik Stage has held roles such as VP, CFO, and CEO in a number of successful international corporations, including Carlsberg Breweries, Hempel Intl, and Santaris Pharma. At Santaris Mr. Stage served as CEO and CFO and closed partnerships with Pfizer, Wyeth, Shire, GlaxoSmithKline and managed the sale and asset transfer to Roche. Currently Mr. Stage serves as CFO at RhoVac and SynAct Pharma.
Lars Stigel, PhD
Lars Stigel is Managing Director of CAPNOVA A/S, a Danish seed investment firm, Chairman of the Board at FOIN, the Association of Innovation Incubators, and a member of the board of Midtjysk Investeringsselskab A/S. Dr. Stigel has more than 20 years’ experience with investments, helping transition emerging companies to successful ventures and ensuring return on investment.
Scientific Advisory Board
Mauro Perretti, PhD
Dr. Perretti is Professor of Immuno Pharmacology at Queen Mary University, London and Dean of Research, Barts and the London School of Medicine. Professor Perretti has several inventions in the field of FPR2-agonists, including co-inventions of several of ResoTher Pharma´s lead compounds. He is a renowned scientist and has published extensively on the role of the naturally occurring peptide Annexin A1 in the resolution of inflammation. Professor Perrettti is the author of more than 300 highly cited publications and is a fellow at the British Pharmacological Society.
Esper Boel, PhD
Dr. Boel is a highly experienced pharmaceutical executive with more than 25 years’ experience in peptide and protein drug discovery for immunological disorders. Dr. Boel was formerly Corporate Vice President for Biotechnology at Novo Nordisk A/S, where he spent many years in the senior R&D leadership team. Dr. Boel then served as Chief Technology Officer and head of Discovery at Symphogen A/S, an immuno-oncology company. Presently, he serves as Chief Science Officer at ParaTech A/S. Dr. Boel has a long track-record of bringing molecules from discovery into human clinical testing for inflammatory disorders.
Anthony Mathur, MD
Dr. Mathur is a clinical cardiologist and the Clinical Director for Interventional Cardiology at Barts Heart Centre where he leads the Cardiovascular Devices Hub at the Centre for Cardiovascular Medicine and Device Innovation. In addition, Dr. Mathur chairs the European Society of Cardiology’s Task Force on stem cells in cardiovascular disease. Dr. Mathur divides his time equally between clinical work, focusing on treatment of heart attack and management of patients with heart failure, and also runs an extensive research programme to develop new biological treatments for patients with heart disease.
Contact ResoTher Pharma
You can find us here:
Dronninggaards Alle 136
For partner inquiries, please contact:
Lone Veng, CEO
+ 45 41 88 95 70
Dronninggaards Alle 136